Core Insights - The report highlights the strategic move of the company to establish an overseas subsidiary and invest in a production base in Morocco, with a total planned investment of up to 20 million USD, aimed at expanding its international market presence [7] - The company has successfully entered the supply chains of major automotive manufacturers, including Renault and Stellantis, indicating a strong foothold in the automotive sector [7] - The company maintains a robust financial position with a net profit margin consistently above 10% since 2022, and cash assets totaling 1.02 billion RMB as of 2024 [8] Company Business Overview - The company is actively implementing a "going out" strategy to enhance its global industrial layout, which is expected to bring new growth opportunities [7] - The company has a strong cost and expense control capability, which has allowed it to sustain a stable profitability [8] - The forecasted net profit for the company from 2025 to 2027 is projected to be 221 million, 256 million, and 299 million RMB respectively, with corresponding EPS of 0.99, 1.15, and 1.34 RMB [9] Industry Insights - The report emphasizes the growing demand for intelligent connected vehicles, which is driving the need for high-performance communication modules [11] - The market for wireless communication modules in intelligent connected vehicles is expected to grow significantly, with a projected compound annual growth rate of 21% from 2020 to 2024, reaching 5 billion RMB by 2024 [11] - The company is positioned to benefit from this trend, having established a leading market share of 35.1% in the 5G vehicle-mounted module sector as of 2024 [12]

中广核核技术发展股份有限公司 关于控股股东向公司子公司增资事项完成工商变更 登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 中广核核技术发展股份有限公司（以下简称"公司"）于 2025 年 6 月 10 日 在证券时报、中国证券报、上海证券报和巨潮资讯网（http://www.cninfo.com.cn） 披露了《关于控股股东向公司全资子公司增资暨关联交易的公告》（公告编号： 拟向公司全资子公司中广核医疗科技（绵阳）有限公司（以下简称"医疗科技公 司"）增资 5 亿元，增资完成后核技术公司持有医疗科技公司 44.13%的股权， 公司持有 55.87%的股权，医疗科技公司仍属于公司的控股子公司。上述事项已 经 2024 年年度股东会审议通过。 近日，核技术公司已向医疗科技公司以现金方式增资 5 亿元，医疗科技公司 已办理完成工商变更登记手续并取得了换发后的《营业执照》。 证券代码：000881 证券简称：中广核技 公告编号：2025-035 特此公告。 中广核核技术发展股份有限公司 董事会 许可项目：第二类医疗器械生产；第三类医疗器械生产；第三类医 ...

中广核核技术发展股份有限公司 关于控股股东向公司子公司增资事项完成工商变更 登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 证券代码：000881 证券简称：中广核技 公告编号：2025-035 许可项目：第二类医疗器械生产；第三类医疗器械生产；第三类医疗器械经 营；Ⅰ类射线装置销售；Ⅱ、Ⅲ类射线装置销售；Ⅱ、Ⅲ类射线装置生产；货物 进出口；技术进出口；进出口代理（依法须经批准的项目，经相关部门批准后方 可开展经营活动，具体经营项目以相关部门批准文件或许可证件为准） 一般项目：机械设备研发；第一类医疗器械生产；第一类医疗器械销售；第 二类医疗器械销售；技术服务、技术开发、技术咨询、技术交流、技术转让、技 术推广；信息技术咨询服务；电子专用设备制造；电子元器件零售；先进电力电 子装置销售；电子专用材料销售；电气设备销售；电气机械设备销售（除依法须 经批准的项目外，凭营业执照依法自主开展经营活动）。 近日，核技术公司已向医疗科技公司以现金方式增资 5 亿元，医疗科技公司 已办理完成工商变更登记手续并取得了换发后的《营业执照》。 1.名称：中广核医疗科 ...

Economic News - In June, the total electricity consumption in China reached 867 billion kWh, a year-on-year increase of 5.4% [1] - The People's Bank of China announced that the 5-year LPR remains at 3.5% and the 1-year LPR at 3% [1] - The U.S. government is reviewing contracts between SpaceX and federal agencies due to concerns over potential waste in multi-billion dollar deals [1] - The Ministry of Transport reported that several key indicators of the "14th Five-Year Plan" have been completed ahead of schedule, including highway mileage and urban rail transit [1] - E-commerce in China saw a growth of 8.5% in online retail sales from January to June 2025, with significant increases in digital products and home appliances [1] - The Ministry of Industry and Information Technology is set to release a plan to stabilize growth in ten key industries, including steel and non-ferrous metals [1] - The European Investment Bank will launch a financing support plan totaling €4.25 billion for renewable energy and green technology investments in EU countries [1] Company News - Yushutech has begun its IPO counseling process with CITIC Securities as the advisor, aiming to submit its application by October 2025 [4] - Suzhou Goodark has been established in Singapore with an investment of approximately 8 million RMB for electronic materials and solar cell production [4] - Hongxin Technology signed contracts with a leading domestic flying car company for the development and procurement of components, which is expected to positively impact its performance [4] - Rainbowsoft's chairman proposed a cash dividend plan for 2025, suggesting a distribution of no less than 60% of the net profit attributable to shareholders [4] - Changyingtong expects revenue between 173 million to 211 million RMB for the first half of 2025, with a significant increase in net profit due to rising demand for optical fiber devices [4] Retail Industry - In June 2025, the total retail sales of consumer goods grew by 4.8% year-on-year, with a slowdown attributed to the earlier "618" shopping festival and weaker restaurant sales [5][6] - Essential consumption remains stable, while optional categories show a slowdown in recovery, with food and daily necessities performing well [6] - Home appliances and furniture sales saw significant growth, with home appliances up 32.4% and furniture up 28.7% year-on-year, driven by government policies [7] - Online retail sales increased by 8.5% in the first half of 2025, with physical goods online sales growing by 6.0%, indicating a steady growth in online consumption [8] - The retail market is expected to continue its recovery, with a focus on durable goods benefiting from policy support and consumer preferences for high-cost performance products [8]

Group 1 - The core viewpoint of the news is that the AI Fund Tongtai New Energy 1-Year Holding Stock A has reported a profit of 186,900 yuan for the second quarter of 2025, with a net asset value growth rate of 0.93% [3] - As of July 18, the fund's unit net value is 0.892 yuan, and the fund manager, Chen Zongchao, has managed four funds with positive returns over the past year [3] - The fund has increased its investment weight in controllable nuclear fusion, which is seen as a potential future energy solution due to its advantages in fuel supply, low emissions, safety, and economic viability [3] Group 2 - As of July 18, the fund's one-year return rate is 18.88%, ranking 23 out of 44 comparable funds [4] - The fund's maximum drawdown since inception is 38.24%, with the largest quarterly drawdown occurring in Q1 2024 at 24.41% [12] - The top ten holdings of the fund as of the end of the second quarter of 2025 include Zhongke Technology, Xuguang Electronics, and others [19]

中广核核技术发展股份有限公司 董事会 2025 年 7 月 17 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 中广核核技术发展股份有限公司（以下简称"公司"）于 2025 年 7 月 16 日 收到公司总法律顾问陈刚先生提交的书面辞职报告，陈刚先生由于工作调整，申 请辞去总法律顾问、总经济师，辞职后仍在公司承担其它专项工作。根据《公司 法》《公司章程》的有关规定，陈刚先生的辞职报告自送达公司董事会之日起生 效。截至本公告披露日，陈刚先生未持有公司股份，但持有公司《股票期权激励 计划》授予的 186,667 份股票期权（激励对象发生职务变更，但未与公司解除或 终止劳动关系的，其获授的股票期权完全按照职务变更前激励计划规定的程序进 行），不存在应当履行而未履行的承诺事项。 公司董事会对陈刚先生在任职期间为公司发展所做出的贡献表示衷心感谢！ 特此公告。 证券代码：000881 证券简称：中广核技 公告编号：2025-034 中广核核技术发展股份有限公司 关于公司总法律顾问辞职的公告 ...

证券代码：000881 证券简称：中广核技 公告编号：2025-033 3.本次会议应出席董事 9 名，实际出席董事 9 名（其中：委托出席的董事 0 名，以通讯表决方式出席会议的董事 6 名，分别为何飞、慕长坤、吴远明、黄晓 延、康晓岳、王满）。 4.本次会议由公司董事长盛国福先生主持。公司董事会秘书及部分高管人员 列席会议。 5.本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件 和《公司章程》的规定。 中广核核技术发展股份有限公司 第十届董事会第二十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、董事会会议召开情况 1.中广核核技术发展股份有限公司（以下简称"公司"）第十届董事会第二 十九次会议（以下简称"本次会议"）通知于 2025 年 7 月 8 日以电子邮件形式 发出。 2.本次会议于 2025 年 7 月 14 日上午 9:00 在深圳市福田区深南大道 2002 号 中广核大厦北楼 19 层 881 会议室以现场结合通讯表决方式召开。 表决情况：9 票同意、0 票反对、0 票弃权、0 票回避 二、董事会会议审 ...

CGNNT 总经理工作细则 版次：4 页：1/7 067-GN-P-TD-B21-124 中广核核技术发展股份有限公司 总经理工作细则 第一章 总则 第一条 为深入贯彻习近平新时代中国特色社会主义思想，把加强党的领导和完善公司治理 统一起来，深化中国特色现代企业制度建设，加快形成权责法定、权责透明、协调运转、有效 制衡的公司治理机制，提高决策效率和科学决策水平，规范中广核核技术发展股份有限公司（以 下简称"公司"）总经理及其他经营层成员依法行使职权、履行职责，根据《中华人民共和国公 司法》、《上市公司治理准则》以及《中广核核技术发展股份有限公司公司章程》（以下简称《公 司章程》）等相关规定，特制定本工作细则。 第二条 公司依据《公司章程》设置总经理一名，由董事长提名，由董事会聘任或解聘。公 司总经理对董事会负责，根据公司章程的规定或者董事会的授权行使职权。总经理列席董事会 会议。 第二章 总经理任职资格 第三条 总经理任职应当具备下列条件： （一）具有较丰富的经济理论知识、管理知识及实践经验，具有较强的经营管理能力； （二）具有调动员工积极性、建立合理的组织机构、协调各种内外关系和统揽全局的能力； （三）具有 ...

Performance Forecast - The company expects a net loss in the current reporting period, with estimated losses ranging from 90 million to 120 million yuan, compared to a loss of 86.58 million yuan in the same period last year [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be a loss between 100 million and 130 million yuan, compared to a loss of 131.47 million yuan in the previous year [1] - Basic earnings per share are expected to be a loss between 0.0952 yuan and 0.1269 yuan, compared to a loss of 0.0916 yuan in the same period last year [1] Reasons for Performance Changes - The overall performance did not meet expectations due to several factors, despite some business segments showing positive development, such as the new materials business [1] - The expansion of the sub-therapeutic equipment market and core technology research, along with continuous investment in new isotope preparation technology, led to an increase in losses in that business segment [1] - The optical multiplier business has not yet achieved profitability due to increased R&D investment aimed at improving production line yield [1] - A decrease in the number of accelerator deliveries compared to the previous year resulted in temporary losses for that segment [1] - A reduction in government subsidies recognized in the current period also contributed to the overall losses [1]

[Estimated Performance for the Current Period](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company projects a net loss attributable to shareholders for H1 2025, with non-recurring net loss expected to narrow compared to the prior year - The performance forecast covers the period from January 1, 2025, to June 30, 2025[2](index=2&type=chunk) Key Financial Performance Indicators | Item | Current Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | Loss: RMB 90.00 million to RMB 120.00 million | Loss: RMB 86.5778 million | | **Net Profit After Non-Recurring Items** | Loss: RMB 100.00 million to RMB 130.00 million | Loss: RMB 131.4708 million | | **Basic Earnings Per Share** | Loss: RMB 0.0952/share to RMB 0.1269/share | Loss: RMB 0.0916/share | [Communication with Accounting Firm](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8E%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%B2%9F%E9%80%9A%E6%83%85%E5%86%B5) The performance forecast data is a preliminary estimate by the company and has not been audited by a certified public accountant - This performance forecast has not been audited by a certified public accountant[3](index=3&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) Despite growth in new materials, overall performance fell short due to increased R&D investment in early-stage medical health and silicon photomultiplier businesses, temporary losses in accelerator operations, and a significant decrease in non-recurring government subsidies - Overall company performance fell short of expectations, primarily impacted by the following business areas: - **Medical Health Business**: Still in its early industrialization phase, current period losses expanded year-over-year due to increased investment in proton therapy equipment market expansion, core technology R&D, and isotope business layout[4](index=4&type=chunk) - **Silicon Photomultiplier Business**: In its incubation phase, it has not yet achieved profitability due to continuous investment in independent breakthroughs for critical product components and improvements in production line yield[4](index=4&type=chunk) - **Accelerator and Irradiation Business**: Due to adjustments in some client delivery schedules, the number of accelerator deliveries decreased year-over-year, resulting in a temporary loss during the reporting period[5](index=5&type=chunk) - **Non-Recurring Gains and Losses**: Government subsidies recognized in current period profit and loss significantly decreased year-over-year, leading to a substantial decline in non-recurring items compared to the prior period[5](index=5&type=chunk) [Risk Warning](index=2&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company advises that this performance forecast is preliminary, and final financial data will be based on the officially disclosed 2025 semi-annual report, cautioning investors about investment risks - This performance forecast is a preliminary estimate, and the specific financial data will be subject to the company's upcoming 2025 semi-annual report[6](index=6&type=chunk)